BMY 22089
Latest Information Update: 07 Dec 1994
At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 06 Dec 1994 Discontinued-Preclinical for Hypercholesterolaemia in USA (Unknown route)